Terms: = Kidney tumors AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
41 results:
1. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
2. Comparative analyses of the prognosis, tumor immune microenvironment, and drug treatment response between left-sided and right-sided colon cancer by integrating scRNA-seq and bulk RNA-seq data.
Cao L; Zhang S; Yao D; Ba Y; Weng Q; Yang J; Zhang H; Ren Y
Aging (Albany NY); 2023 Jul; 15(14):7098-7123. PubMed ID: 37480572
[TBL] [Abstract] [Full Text] [Related]
3. Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort study.
Myint KZY; Shimabuku M; Horio R; Kaneda M; Shimizu Y; Taguchi J
Cancer Treat Res Commun; 2023; 35():100701. PubMed ID: 37094468
[TBL] [Abstract] [Full Text] [Related]
4. Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Ng KW; Boumelha J; Enfield KSS; Almagro J; Cha H; Pich O; Karasaki T; Moore DA; Salgado R; Sivakumar M; Young G; Molina-Arcas M; de Carné Trécesson S; Anastasiou P; Fendler A; Au L; Shepherd STC; Martínez-Ruiz C; Puttick C; Black JRM; Watkins TBK; Kim H; Shim S; Faulkner N; Attig J; Veeriah S; Magno N; Ward S; Frankell AM; Al Bakir M; Lim EL; Hill MS; Wilson GA; Cook DE; Birkbak NJ; Behrens A; Yousaf N; Popat S; Hackshaw A; ; ; Hiley CT; Litchfield K; McGranahan N; Jamal-Hanjani M; Larkin J; Lee SH; Turajlic S; Swanton C; Downward J; Kassiotis G
Nature; 2023 Apr; 616(7957):563-573. PubMed ID: 37046094
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract] [Full Text] [Related]
6. The Possible Connection of Two Dual Function Processes: The Relationship of Ferroptosis and the JNK Pathway.
Varga D; Hajdinák P; Makk-Merczel K; Szarka A
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232313
[TBL] [Abstract] [Full Text] [Related]
7. ABCB1 limits brain exposure of the kras
Loos NHC; Retmana IA; Li W; Martins MLF; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2022 Apr; 178():106137. PubMed ID: 35192958
[TBL] [Abstract] [Full Text] [Related]
8. Soluble PD-L1 as an early marker of progressive disease on nivolumab.
Mahoney KM; Ross-Macdonald P; Yuan L; Song L; Veras E; Wind-Rotolo M; McDermott DF; Stephen Hodi F; Choueiri TK; Freeman GJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131863
[TBL] [Abstract] [Full Text] [Related]
9. [Papillary renal neoplasm with reverse polarity: a clinicopathological analysis].
Ji RH; Wang XT; Li R; Ye SB; Wang X; Ma HH; Lu ZF; Rao Q; Xia QY
Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):23-27. PubMed ID: 34979749
[No Abstract] [Full Text] [Related]
10. Sotorasib for previously treated colorectal cancers with kras
Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
[TBL] [Abstract] [Full Text] [Related]
11. Oncogenic kras is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
[TBL] [Abstract] [Full Text] [Related]
12. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma.
Sun G; Chen J; Liang J; Yin X; Zhang M; Yao J; He N; Armstrong CM; Zheng L; Zhang X; Zhu S; Sun X; Yang X; Zhao W; Liao B; Pan X; Nie L; Yang L; Chen Y; Zhao J; Zhang H; Dai J; Shen Y; Liu J; Huang R; Liu J; Wang Z; Ni Y; Wei Q; Li X; Zhou Q; Huang H; Liu Z; Shen P; Chen N; Zeng H
Nat Commun; 2021 Sep; 12(1):5262. PubMed ID: 34489456
[TBL] [Abstract] [Full Text] [Related]
13. Case report: Rare myeloid sarcoma development following renal transplantation with kras and DNMT3A gene mutations.
Wu D; Lu X; Yan X; Gao R
Diagn Pathol; 2021 Aug; 16(1):82. PubMed ID: 34465355
[TBL] [Abstract] [Full Text] [Related]
14. kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, kras and AKT in renal cell carcinoma.
Li F; Aljahdali IAM; Zhang R; Nastiuk KL; Krolewski JJ; Ling X
J Exp Clin Cancer Res; 2021 Aug; 40(1):254. PubMed ID: 34384473
[TBL] [Abstract] [Full Text] [Related]
15. Nonclinical Safety Profile of Sotorasib, a kras
Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
[TBL] [Abstract] [Full Text] [Related]
16. Targeting kras Mutant Cancers via Combination treatment: Discovery of a 5-Fluoro-4-(3
Huestis MP; Dela Cruz D; DiPasquale AG; Durk MR; Eigenbrot C; Gibbons P; Gobbi A; Hunsaker TL; La H; Leung DH; Liu W; Malek S; Merchant M; Moffat JG; Muli CS; Orr CJ; Parr BT; Shanahan F; Sneeringer CJ; Wang W; Yen I; Yin J; Siu M; Rudolph J
J Med Chem; 2021 Apr; 64(7):3940-3955. PubMed ID: 33780623
[TBL] [Abstract] [Full Text] [Related]
17. The effect of microRNA-330 replacement on inhibition of growth and migration in renal cancer cells.
Liu J; Song X; Ren Z
Biotechnol Appl Biochem; 2022 Apr; 69(2):558-566. PubMed ID: 33605482
[TBL] [Abstract] [Full Text] [Related]
18. Cell autonomous angiotensin II signaling controls the pleiotropic functions of oncogenic K-Ras.
Volonte D; Sedorovitz M; Cespedes VE; Beecher ML; Galbiati F
J Biol Chem; 2021; 296():100242. PubMed ID: 33380422
[TBL] [Abstract] [Full Text] [Related]
19. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
[TBL] [Abstract] [Full Text] [Related]
20. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
[No Abstract] [Full Text] [Related]
[Next]
